Corbus Pharmaceuticals Holdingsincis A Clinical Stage Biopharmaceutical Company Based In Norwoodmassachusettsthe Company Is Dedicated To Developing Innovative Therapeutics For Chronic Inflammatoryfibroticand Oncological Diseasescorbus Operates In The Biopharmaceutical Sector And Is Publicly Traded On Nasdaq Under The Symbol Crbp The Company S Pipeline Includes Lenabasuma Selective Cannabinoid Receptor Type 2Cb2Agonist Aimed At Treating Chronic Inflammatory And Fibrotic Diseases Such As Dermatomyositis And Systemic Lupus Erythematosuscorbus Is Also Advancing Oncology Programsincluding A Next Generation Nectin 4 Antibody Drug Conjugate And Monoclonal Antibodies Targeting Tumor Progression Pathwaysadditionallycrb 913A Cb1 Inverse Agonistis In Phase 1 Trials For Obesitycorbus Focuses On Addressing High Unmet Medical Needs In Rarelife Threatening Conditions And Emphasizes Partnerships And Regulatory Milestones To Advance Its Drug Development Efforts
